Phase 2 Retinal Vein Occlusion and Diabetic Macular Oedema Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are willing and able to provide written consent to take part in the study.
• People who understand the full study process, agree to take their medications as directed, complete all required assessments on time, and follow all study rules including restrictions on other medications.
• People who have been diagnosed with type 1 or type 2 diabetes, have a blood sugar control measure (HbA1c) of 10.0% or below, and have had stable blood sugar levels on their current diabetes medications for at least one month before screening.
• People whose vision loss in the eye being studied is mainly caused by diabetic macular edema (a condition where fluid builds up in the central part of the retina due to diabetes).
• People whose vision in the eye being studied falls within a specific range — not better than 20/40 and not worse than 20/320 on a standard eye chart — at both the screening and baseline visits.
• People whose eye scan (a type of retinal imaging called OCT) shows that the central retinal thickness in the eye being studied is 300 micrometres or more at screening.

Who may not be able to join:

• People whose eye being studied has any other eye disease or condition (apart from diabetic macular edema) that causes or could cause permanent vision loss.
• People whose eye being studied has had glaucoma drainage surgery in the past, or where such surgery is planned during the study.
• People whose eye being studied has previously had surgery inside the eye involving the vitreous or retina.
• People whose eye being studied received steroid (hormone) medication injected inside the eye within 6 months before the baseline visit, or around the eye or by mouth/body within 3 months before baseline.
• People whose either eye received an injection of a VEGF-blocking drug inside the eye within 3 months before the baseline visit.
• People with a history of a certain type of eye inflammation (uveitis) that is autoimmune or of unknown cause, in either eye.
• People with uncontrolled glaucoma in either eye, meaning eye pressure remains at or above 25 mmHg even after treatment with glaucoma medications.
• People with a known allergy to the study drug, any of its ingredients, or any substances used during the treatment process.
• People who have taken part in another clinical trial of an investigational drug or device within 3 months before baseline, or within 5 half-lives of that drug — whichever period is longer.
• People who the investigator considers unsuitable for the trial for any other reason.

Important: Always verify eligibility with the trial site directly before applying.